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S100A13, a member of the S100 gene family of Ca21-
binding proteins has been previously characterized as a
component of a brain-derived heparin-binding multi-
protein aggregate/complex containing fibroblast growth
factor 1 (FGF1). We report that while expression of
S100A13 in NIH 3T3 cells results in the constitutive re-
lease of S100A13 into the extracellular compartment at
37 °C, co-expression of S100A13 with FGF1 represses the
constitutive release of S100A13 and enables NIH 3T3
cells to release S100A13 in response to temperature
stress. S100A13 release in response to stress occurs with
kinetics similar to that observed for the stress-induced
release of FGF1, but S100A13 expression is able to re-
verse the sensitivity of FGF1 release to inhibitors of
transcription and translation. The release of FGF1 and
S100A13 in response to heat shock results in the solubil-
ity of FGF1 at 100% (w/v) ammonium sulfate saturation,
and the expression of a S100A13 deletion mutant lacking
its novel basic residue-rich domain acts as a dominant
negative effector of FGF1 release in vitro. Surprisingly,
the expression of S100A13 also results in the stress-in-
duced release of a Cys-free FGF1 mutant, which is nor-
mally not released from NIH 3T3 cells in response to
heat shock. These data suggest that S100A13 may be a
component of the pathway for the release of the signal
peptide-less polypeptide, FGF1, and may involve a role
for S100A13 in the formation of a noncovalent FGF1
homodimer.
FGF11 and FGF2 are the prototype members of a large
family of heparin-binding growth factor genes that regulate
numerous biological processes such as neurogenesis, mesoderm
formation, and angiogenesis (1, 2). FGF1 and FGF2 lack a
classical signal peptide sequence that provides access to the
conventional endoplasmic reticulum (ER)-Golgi secretion path-
way, a characteristic that led to the hypothesis that the release
of these polypeptides may proceed through novel release/export
pathways (2). Our laboratory previously demonstrated that
FGF1, but not FGF2, is released as a latent homodimer by a
transcription- and translation-dependent mechanism in re-
sponse to a variety of cellular stresses including heat shock (3),
hypoxia (4), and serum starvation (5). Conversely, the disrup-
tion of communication between the ER and Golgi apparatus by
brefeldin A does not prevent the release of FGF1 from NIH 3T3
cells, confirming that FGF1 release may occur through a non-
conventional pathway (6).
FGF1 is released in vitro as a reducing agent- and denatur-
ant-sensitive complex, which contains the p40 extravesicular
domain of the Ca21-binding protein, p65 synaptotagmin (Syt)1
(7). The release of FGF1 in response to stress is dependent on
Syt1 expression, since the expression of either a deletion mu-
tant lacking 95 amino acids from the extravesicular portion of
Syt1 or an antisense-Syt1 gene is able to repress FGF1 release
in NIH 3T3 cells (7, 8). In addition, FGF1 purified from ovine
brain as a high molecular weight aggregate exists as a compo-
nent of a noncovalent heparin-binding complex with p40 Syt1
and S100A13 (9).
The interleukin (IL)-1 gene family of proinflammatory
polypeptides also contains functional cytokines that act as ex-
tracellular, receptor-dependent mediators of cellular function
(10, 11), yet the majority of the members of the IL-1 gene family
lack a classical signal peptide sequence for conventional secre-
tion (10, 11). Interestingly, crystallographic analysis of the
FGF and IL-1 prototypes demonstrates a remarkable level of
structural similarity between these seemingly disparate
polypeptides (12, 13). Recent studies have suggested that the
pathway utilized for the release of IL-1a is quite similar yet
distinct from the pathway utilized by FGF1 export, since both
proteins are released in response to temperature stress with
similar biochemical and pharmacologic properties (14). In con-
trast, however, the IL-1a release pathway requires the proteo-
lytic processing of the 31-kDa precursor form of IL-1a to the
17-kDa mature form for IL-1a release and does not appear to
utilize Syt1 for export, since a dominant negative Syt1 mutant
blocks FGF1 but not IL-1a release (14). Although we have not
been able to eliminate the function of other Syt gene family
members in the stress-induced release of IL-1a, the observation
that the precursor form of IL-1a is able to block the release of
FGF1 in response to temperature stress suggests that the
FGF1 and IL-1a release pathways may be mechanistically
linked (14).
Recently, we have reported that amlexanox, an anti-allergic
drug that binds S100A13 (15), is able to inhibit the release of
FGF1 and p40 Syt1 in response to temperature stress (9, 16).
Because amlexanox also induces a Src-dependent and reversi-
ble disassembly of actin stress fibers (16), these data have
suggested a role for the actin cytoskeleton in the regulation of
FGF1 release (16).
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S100A13 is a member of a large gene family of Ca21-binding
proteins characterized by the absence of a classical signal pep-
tide sequence and the presence of two Ca21-binding EF-hand
domains (17, 18). S100A13 is a novel member of the S100 gene
family that encodes a protein containing a positively charged
carboxyl-terminal domain that may be involved in specific pro-
tein interactions (19). While members of the S100 gene family,
including S100A13 (20), are expressed in a variety of tissues
and organs (17, 18), the expression of a few members of the
S100 gene family have been implicated in the regulation of
human pathology including neurodegenerative diseases, car-
diomyopathies, cancer, and chronic inflammation (17, 18). In-
terestingly, members of the S100 gene family have been shown
to be constitutively released into the extracellular compart-
ment (17, 18, 21), where they have been characterized as leu-
kocyte chemoattractants and regulators of macrophage activa-
tion (17, 18, 22).
Since S100A13 was purified from the ovine brain as a part of
the multiprotein aggregate containing FGF1 and p40 Syt1, we
sought to determine whether S100A13 is involved in the re-
lease of FGF1. We report that S100A13 expression facilitates
the release of FGF1 into the extracellular compartment in
response to temperature stress in vitro and that S100A13 ex-
pression is able to revert the dependence for both transcription
and translation in the release of FGF1 in response to heat
shock. We further describe the unanticipated observation that
S100A13 expression is able to export a Cys-free FGF1 mutant,
suggesting that S100A13 may be involved in the formation of
the FGF1 homodimer, a prerequisite for export.
MATERIALS AND METHODS
Plasmid Constructs—The plasmid pT7T3-S100A13 containing the
cDNA encoding murine S100A13 was a generous gift from Dr. Beat W.
Schafer (University of Zurich, Switzerland), and all restriction enzymes
were obtained from New England Biolabs. The S100A13 cDNA was
obtained by digesting the pT7T3-S100A13 plasmid with NotI and
BstZ17I. The fragment was cloned into the pCS2–6-Myc tag vector
digested with EcoRI, filled-in by the Klenow reaction (New England
Biolabs Inc.), and digested with NotI. The Myc tag was ligated at the
amino terminus of the S100A13 protein and consisted of a 13-amino
acid epitope (MEQKLISEEDLNE) repeated six times and recognized by
the 9E10 monoclonal anti-Myc antibody (Oncogene Research Products).
For expression in mammalian cells, the Myc-S100A13 DNA was di-
gested using HindIII and ligated into the pcDNA3.1-Hygro (1) vector
(Invitrogen) also excised with HindIII. For expression in prokaryotic
cells, S100A13 cDNA was digested from pT7T3-S100A13 using HindIII
and BstZ17I. The fragment was ligated into the prokaryotic expression
vector, pGEX-KG, digested with XbaI, filled-in by the Klenow reaction,
and further digested with HindIII. The pGEX-KG vector contains the
sequence encoding for the glutathione S-transferase (GST) that was
used to purify the recombinant S100A13. For the preparation of the
S100A13D88–98 mutant, the plasmid pT7T3-S100A13 was digested
with BsaBI and PpuMI, and the S100A13 fragment was purified by gel
electrophoresis. Two oligonucleotides lacking the sequence encoding for
the last 11 amino acids of S100A13 were ligated in the digested plasmid.
The two oligonucleotides and their complementary chains were de-
signed with a BsaBI site at the 59-end and a PpuMI site at the 39-end
and with a complementary overlapping sequence in the middle. The
sequences of the oligonucleotides used are as follows: 59-GAATCAGG-
ACTCAGAGCTGAGGTTCAGTGAATACTGGAGACTGAT-39; 59-AGT-
ATTCACTGAACCTCAGCTCTGAGTCCTGATTC-39; 59-TGGAGAGCT-
GGCAAAGGAAGTCTAAAGCTTGCTGTCCAGCAG-39; 59-GTCCTGC-
TGGACAGCAAGCTTTAGACTTCCTTTGCCAGCTCTCCAATCAGTC-
TCC-39. The S100A13D88 –98 construct was ligated into the
pCS2–6Myc tag vector with the six-Myc tag repeat sequence fused at
the amino terminus of the protein and the Myc-S100A13D88–98 se-
quence cloned into the pcDNA3.1-Hygro (1) expression vector as de-
scribed above.
Cell Culture—Murine NIH 3T3 cells were obtained from the Ameri-
can Type Culture Collection (ATCC) and grown as previously described
(3). NIH 3T3 cells, FGF1 NIH 3T3 (3), and Cys-free FGF1 NIH 3T3 cell
transfectants (6) were cotransfected with the gene encoding murine
Myc-S100A13 cloned into the pcDNA3.1-Hygro (1) vector or with the
insertless expression vector. FGF1 NIH 3T3 cells were also transfected
with the same eukaryotic expression vector containing the DNA se-
quence encoding for the Myc-S100A13D88–98 mutant. All transfections
were performed using a multicomponent lipid-based reagent (FuGENE
6; Roche), and stable clones of the NIH 3T3 cell cotransfectants were
obtained, expanded, and grown in Dulbecco’s modified Eagle’s medium
(Cellgro) supplemented with 10% (v/v) bovine calf serum (HyClone), 13
antibiotic/antimycotic (Life Technologies, Inc.), 0.15 g/liter hygromicin
B (Life Technologies), and 0.4 g/liter Geneticin (G418; Life Technolo-
gies) on human fibronectin-coated dishes (10 mg/cm2).
Temperature Stress, Processing of Conditioned Media, and Immuno-
blot Analysis—NIH 3T3 cell transfectants were grown to 70–80% con-
fluency, and prior to temperature stress, the cells were washed with
Dulbecco’s modified Eagle’s medium containing 5 units/ml heparin (Up-
john). The heat shock was performed as previously described (3, 7, 8) in
Dulbecco’s modified Eagle’s medium containing 5 units/ml heparin for
110 min at 42 °C. Control cultures were incubated at 37 °C in Dulbec-
co’s modified Eagle’s medium containing 5 units/ml heparin. Two inde-
pendent clones from each transfection have been evaluated with similar
results. The effects of 2-deoxyglucose (Sigma), brefeldin A (Epicenter
Technologies), amlexanox (Takeda), latrunculin (Molecular Probes,
Inc., Eugene, OR), actinomycin D (Sigma), and cycloheximide (Sigma)
on FGF1 and Myc-S100A13 release were evaluated as previously re-
ported (3, 6, 8, 9, 16). Following heat shock, the conditioned media were
collected, filtered, and treated with either 0.1% (w/v) DTT (Sigma) for
2 h at 37 °C or fractionated with ammonium sulfate (Sigma) at 100%
(w/v) saturation as previously described (3, 6). After ammonium sulfate
fractionation, conditioned media were centrifuged at 10,000 3 g for 50
min, and the pellets were resuspended in 20 ml of 50 mM Tris, pH 7.4,
containing 10 mM EDTA (TEB). Pellets and supernatants were dialyzed
against 50 mM Tris, pH 7.4, for 18 h and treated with 0.1% (w/v) DTT for
2 h at 37 °C. DTT- and ammonium sulfate-treated conditioned media
were adsorbed to a heparin-Sepharose CL-6B (1-ml) column (Amer-
sham Pharmacia Biotech), equilibrated with TEB, and the adsorbed
proteins were washed with TEB and eluted with 2.5 ml of TEB contain-
ing NaCl concentrations specified under “Results.” Eluted proteins
were concentrated using Centricon 10 (Amicon, Inc.), resolved by 15%
(w/v) SDS-PAGE, transferred to a nitrocellulose membrane (Hybond C;
Amersham Pharmacia Biotech), and immunoblotted with an anti-Myc
monoclonal antibody (Oncogene Research Products) or an anti-FGF1
polyclonal antibody (23), and bands were visualized by chemilumines-
cence (ECL; Amersham Pharmacia Biotech). Total cell lysates were
obtained from cells incubated at 37 °C by resuspending cell pellets for
20 min in 0.5 ml of cold lysis buffer (20 mM Tris, pH 7.5, containing 300
mM sucrose, 60 mM KCl, 15 mM NaCl, 5% (v/v) glycerol, 2 mM EDTA, 1%
(v/v) Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 2 mg/ml apro-
tinin, 2 mg/ml leupeptin, and 0.2% (w/v) deoxycholate) and analyzed by
immunoblot analysis.
For the analysis of the release of FGF1 and Myc-S100A13D88–98
from NIH 3T3 cell cotransfectants, conditioned media and cell lysates
were divided into two portions, one of which was processed by heparin-
Sepharose adsorption for FGF1 immunoblot analysis and the other
processed by immunoprecipitation with anti-Myc antibody for the de-
tection of Myc-S100A13D88–98 and Myc-S100A13. Briefly, conditioned
media were filtered, treated with 0.1% (w/v) DTT for 2 h at 37 °C, and
concentrated using a centrifugal filter device (Ultrafree-15; Millipore
Corp.) to a volume of ;500 ml, and aprotinin and leupeptin were added
to each sample to yield a final concentration of 2 mg/ml. Cell lysates and
concentrated conditioned media were rotated for 18 h at 4 °C in the
presence of 1 mg of mouse anti-Myc antibody. Protein A-Sepharose
(Amersham Pharmacia Biotech) was added, and the samples were
rotated for an additional 2 h at 4 °C. Immunoprecipitated proteins were
eluted with sample buffer, boiled, resolved by 12% (w/v) SDS-PAGE,
and immunoblotted with anti-Myc antibody. The activity of lactate
dehydrogenase (Sigma) in conditioned media was utilized as an assess-
ment of cell lysis in all experiments as previously reported (24).
Purification of Recombinant S100A13, Preparation of S100A13 An-
tiserum, and Analysis of S100A13 Heparin Affinity—The GST-S100A13
fusion protein was generated as described above (25), with the excep-
tion that the BL21 E. coli were lysed in 50 mM Tris buffer, pH 8.8,
containing 10 mM EDTA, 10 mM glucose, and 10 mg/ml lysozyme, and
the thrombin-cleaved S100A13 protein was further purified by C8
(PerkinElmer Life Sciences) reverse-phase high pressure liquid chro-
matography as previously described for FGF1 (26). Female 6-month-old
New Zealand White rabbits (Hazelton Research Animals) were injected
intradermally with 1 mg of recombinant S100A13 suspended in
Freund’s complete adjuvant (Calbiochem) and boosted with 200 mg of
protein suspended in Freund’s incomplete adjuvant (Calbiochem). The
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antibody was purified by incubating the serum with immobilized re-
combinant S100A13 on a Problot polyvinylidene difluoride membrane
(Applied Biosystem Inc.) blocked at 42 °C with 24 mM Tris, pH 7.4,
containing 136 mM NaCl, 2 mM KCl, 0.1% (v/v) Tween 20, and 5% (w/v)
bovine serum albumin. The membrane was washed three times with
0.05% (v/v) Triton X-100 in 50 mM Tris, pH 7.4, containing 150 mM
NaCl, and the antibody was eluted with 0.2 M glycine, pH 2.8, and
neutralized with 1 M K2HPO4, pH 7.4. For the evaluation of S100A13
heparin affinity, 5 mg of recombinant S100A13 were adsorbed to hepa-
rin-Sepharose (1 ml), previously equilibrated with TEB. The adsorbed
proteins were washed with TEB and eluted with 2.5 ml of TEB contain-
ing increasing concentrations of NaCl. Eluted proteins were concen-
trated using Centricon 3 (Amicon, Inc.), resolved by 15% (w/v) SDS-
PAGE, and immunoblotted with the rabbit anti-S100A13 antibody.
RESULTS
S100A13 Exhibits Low Heparin Affinity and Is Constitutively
Released in Vitro—Because we have previously characterized
ovine brain-derived S100A13 as a component of a high affinity
heparin-binding multiprotein aggregate/complex containing
FGF1 and the p40 extravesicular domain of p65 Syt1 (9), we
sought to characterize the heparin-binding character of
S100A13. As shown in Fig. 1A, while recombinant murine
S100A13 was able to bind heparin-Sepharose, its affinity for
heparin was low, since S100A13 immunoblot analysis reported
its presence in the 0.5 M NaCl elution fraction. Thus, like p40
Syt1 (7), brain-derived S100A13 (9) may gain heparin affinity
by its ability to associate either directly or indirectly with p40
Syt1 and/or FGF1.
Because the level of endogenous S100A13 expression in NIH
3T3 cells is low (data not shown), we constructed a chimera in
which six copies of the Myc epitope were fused at the 59-end of
the S100A13 cDNA and obtained stable Myc-S100A13 NIH 3T3
cell transfectants and FGF1 and Myc-S100A13 NIH 3T3 cell
cotransfectants. As a control, we also obtained FGF1 NIH 3T3
cells cotransfected with the insert-less vector used to transfect
the Myc-S100A13 cDNA. Myc immunoblot analysis of cell ly-
sates from Myc-S100A13 NIH 3T3 cell transfectants, Myc-
S100A13 and FGF1 NIH 3T3 cell cotransfectants, and insert-
less vector and FGF1 NIH 3T3 cell cotransfectants confirmed
the expression of Myc-S100A13 as a polypeptide with an ap-
parent molecular mass of 27 kDa in the Myc-S100A13 NIH 3T3
cell transfectants (Fig. 2B) and Myc-S100A13 and FGF1 NIH
3T3 cell cotransfectants (Fig. 2A). This band was not present in
cell lysates derived from the insert-less vector and FGF1 NIH
3T3 cell cotransfectants (Fig. 2A). Myc epitope immunoblot
analysis demonstrated a slight retardation in the electro-
phoretic mobility of Myc-S100A13 from the expected molecular
mass of 21 kDa, an alteration that may be due to a change in
the conformation of the protein upon binding to metal ions.
Indeed, this observation is consistent with similar alterations
established for a variety of other S100 proteins (27–29). As
shown in Fig. 1B, the Myc-S100A13 chimera obtained from
lysates of Myc-S100A13 NIH 3T3 cell transfectants exhibited
similar heparin affinity as the S100A13 recombinant protein
purified from the prokaryotic expression system. Because tem-
perature stress of the Myc-S100A13 NIH 3T3 cell transfectants
did not alter the heparin affinity of the Myc-S100A13 chimera
(Fig. 1B), we suggest that the Myc-S100A13 protein may not be
FIG. 1. The heparin affinity of S100A13. A, recombinant S100A13
was obtained as described under “Materials and Methods,” and 5 mg of
recombinant S100A13 was adsorbed to heparin-Sepharose, eluted with
0.5, 1.0, and 1.5 M NaCl as described (7); the fractions were resolved by
15% (w/v) SDS-PAGE and subjected to S100A13 immunoblot analysis
using a rabbit anti-S100A13 antibody. Lane 1, 5 mg of recombinant
S100A13; lane 2, 0.5 M NaCl fraction; lane 3, 1.0 M NaCl fraction; lane
4, 1.5 M NaCl fraction; lane 5, flow-through fraction. B, Myc-S100A13
NIH 3T3 cell transfectants were subjected to heat shock (110 min at
42 °C), and cell lysates were obtained from control (37 °C) and stressed
cultures as described under “Materials and Methods.” Proteins were
adsorbed to heparin-Sepharose, eluted at 0.5, 1.0, and 1.5 M NaCl, and
resolved by 15% (w/v) SDS-PAGE. Myc-S100A13 was evaluated by Myc
immunoblot analysis. Lane 1, 0.5 M NaCl fraction from control cells;
lane 2, 1.0 M NaCl fraction from control cells; lane 3, 1.5 M NaCl fraction
from control cells; lane 4, 0.5 M NaCl fraction from heat-shocked cells;
lane 5, 1.0 M NaCl fraction from heat-shocked cells; lane 6, 1.5 M NaCl
fraction from heat-shocked cells.
FIG. 2. The release of Myc-S100A13 in response to temperature
stress. A and B, S100A13 is released with a Myc reporter in response
to heat shock. Myc-S100A13 and FGF1 NIH 3T3 cell cotransfectants
and insert-less vector and FGF1 NIH 3T3 cell cotransfectants (A) and
Myc-S100A13 NIH 3T3 cell transfectants (B) were either subjected to
heat shock (110 min at 42 °C) or incubated for 110 min at 37 °C.
Conditioned media were treated with 0.1% DTT, adsorbed to heparin-
Sepharose, and eluted at 1.5 M NaCl. Eluted proteins were concen-
trated, resolved by 15% (w/v) SDS-PAGE, and analyzed by FGF1 and
Myc immunoblot analysis. A, upper panel, FGF1 immunoblot analysis;
lower panel, Myc immunoblot analysis. Lane 1, total cell lysate from
Myc-S100A13 and FGF1 NIH 3T3 cotransfectants; lane 2, total cell
lysate from insert-less vector and FGF1 NIH 3T3 cotransfectants; lanes
3 and 4, media conditioned at 37 and 42 °C from Myc-S100A13 and
FGF1 NIH 3T3 cotransfectants; lanes 5 and 6, media conditioned at 37
and 42 °C from insert-less vector and FGF1 NIH 3T3 cotransfectants.
B, lane 1, total cell lysate from Myc-S100A13 NIH 3T3 transfectants;
lanes 2 and 3, media conditioned at 37 and 42 °C from Myc-S100A13
NIH 3T3 transfectants. C, the kinetics of FGF1 and Myc-S100A13
release in response to temperature stress. Myc-S100A13 and FGF1 NIH
3T3 cell cotransfectants were subjected to heat shock for 10 (lane 2), 20
(lane 3), 30 (lane 4), 60 (lane 5), and 90 (lane 6) min or incubated for 90
min at 37 °C (lane 1). Conditioned media were processed as described
above and analyzed by FGF1 (upper panel) and Myc (lower panel)
immunoblot analysis.
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subjected to temperature-mediated post-translational modifi-
cations, which may affect its heparin affinity.
We have previously reported that NIH 3T3 cells transfected
with FGF1 and p65 Syt1 are able to release FGF1 and the p40
extravesicular domain of Syt1 in response to cellular stress (7,
8) and that FGF1 and the p40 extravesicular domain of p65
Syt1 are present in the extracellular compartment as a reduc-
ing agent- and denaturant-sensitive complex (7). Because the
expression of p40 Syt1 in NIH 3T3 cells results in the stress-
independent, constitutive release of p40 Syt1 (8), we ques-
tioned whether Myc-S100A13 may also be able to access the
extracellular compartment either spontaneously or under con-
ditions of temperature stress. Myc-S100A13 NIH 3T3 cell
transfectants were subjected to heat shock (110 min at 42 °C)
or maintained for 110 min at 37 °C, and conditioned media
were treated with 0.1% (w/v) DTT, adsorbed to heparin-Sepha-
rose, eluted at 1.5 M NaCl, and analyzed for Myc-S100A13
release by immunoblot analysis. As shown in Fig. 2B, we ob-
served that Myc-S100A13 was present in media conditioned
independently of temperature stress and that stress conditions
did not significantly increase the level of Myc-S100A13 in the
extracellular compartment. Kinetic analysis of the tempera-
ture-independent Myc-S100A13 release from Myc-S100A13
NIH 3T3 cell transfectants demonstrated that Myc-S100A13
was detectable in media conditioned at 37 °C after 30 min with
an increase in the level of extracellular Myc-S100A13 observed
after prolonged time periods (hours) at 37 °C (data not shown).
FGF1 Is Able to Repress the Constitutive Release of
S100A13—The Myc-S100A13 and FGF1 NIH 3T3 cell cotrans-
fectants were also subjected to heat shock in order to study the
simultaneous release of Myc-S100A13 and FGF1. Conditioned
media were obtained from both Myc-S100A13 and FGF1 and
insert-less vector and FGF1 NIH 3T3 cell cotransfectants fol-
lowing heat shock and processed for FGF1 and Myc immuno-
blot analysis. We observed that both cotransfectants released
similar levels of FGF1 in response to stress, and the Myc-
S100A13 and FGF1 NIH 3T3 cell cotransfectants also released
the Myc-S100A13 chimera in response to temperature stress
(Fig. 2A). The Myc-S100A13 and FGF1 NIH 3T3 cell cotrans-
fectants were further evaluated for the capacity to constitu-
tively release Myc-S100A13 independent of stress, and Myc
immunoblot analysis was able to detect the presence of Myc-
S100A13 only in media conditioned at 37 °C for time periods
greater than 8 h (data not shown). Further, FGF1 immunoblot
analysis revealed that FGF1 was not present in media condi-
tioned at 37 °C for this prolonged time period (data not shown).
These data suggest that (i) the constitutive release of Myc-
S100A13 at 37 °C is significantly impaired but is up-regulated
in response to stress in a FGF1-rich background represented by
the Myc-S100A13 and FGF1 NIH 3T3 cell cotransfectants and
(ii) the constitutive release of Myc-S100A13 occurs unattenu-
ated in a FGF1-poor background represented by the Myc-
S100A13 NIH 3T3 cell transfectants.
Because FGF1 and p40 Syt1 are known to be released in
response to heat shock with rather slow kinetics (8), we eval-
uated whether the stress-induced release of Myc-S100A13 also
proceeds with similar kinetics. The Myc-S100A13 and FGF1
NIH 3T3 cell cotransfectants were subjected to heat shock for
10, 20, 30, 60, and 90 min, and the conditioned media were
processed for FGF1 and Myc immunoblot analysis. As shown in
Fig. 2C, both FGF1 and Myc-S100A13 were released with sim-
ilar kinetics, and both required at least 90 min of exposure to
temperature stress to gain access to the extracellular compart-
ment. These results suggest that FGF1 (6), p40 Syt1 (8), and
Myc-S100A13 also exhibit similar kinetics of release from NIH
3T3 cells in response to stress when NIH 3T3 cell Myc-S100A13
transfectants are cotransfected with FGF1.
The Expression of Myc-S100A13 Overcomes the Transcrip-
tional and Translational Requirements for FGF1 Release in
Response to Heat Shock—Since we have previously reported
that the release of FGF1 and p40 Syt1 is dependent on tran-
scription and translation (3, 8), we evaluated the effect of
actinomycin D and cycloheximide on the heat shock-induced
release of Myc-S100A13 and FGF1. Myc-S100A13 and FGF1
NIH 3T3 cell cotransfectants and insert-less vector and FGF1
NIH 3T3 cell cotransfectants were subjected to heat shock in
the presence and absence of actinomycin D (10 mg/ml) or cyclo-
heximide (10 mg/ml), and conditioned media were analyzed for
FGF1 and Myc-S100A13 release by immunoblot analysis. We
observed that FGF1 NIH 3T3 cells cotransfected with Myc-
S100A13 were able to release FGF1 and Myc-S100A13 in re-
sponse to heat shock in the presence of either actinomycin D or
cycloheximide (Fig. 3B). In contrast, the treatment of insert-
less vector and FGF1 NIH 3T3 cell cotransfectants with acti-
nomycin D and cycloheximide completely inhibited FGF1 re-
lease (Fig. 3A). Because these data demonstrated that Myc-
S100A13 expression was able to revert the sensitivity of FGF1
release to actinomycin D and cycloheximide, we evaluated
whether S100A13 gene expression was induced during heat
shock. However, analysis of the steady-state levels of the tran-
scripts for S100A13 at 37 and 42 °C demonstrated that
S100A13 is not a heat shock gene (data not shown). Thus, we
suggest that the ability of Myc-S100A13 expression to revert
the actinomycin D- and cycloheximide-sensitive component of
the FGF1 release pathway may be due to a heat shock-induced
post-translational event mediated by S100A13.
Because we have previously reported that the stress-medi-
ated release of FGF1 and p40 Syt1 requires the biosynthesis of
ATP (8), is sensitive to reagents that affect the integrity of the
actin cytoskeleton (9, 16), and is not affected by brefeldin A (8),
a reagent that disrupts communication between the ER-Golgi
apparatus (30), we sought to determine whether the stress-
induced release of Myc-S100A13 exhibited similar behavior.
Thus, Myc-S100A13 and FGF1 NIH 3T3 cell cotransfectants
were subjected to heat shock in the presence and absence of the
appropriate biochemical reagent, and their conditioned media
were subjected to Myc and FGF1 immunoblot analysis. As
shown in Fig. 3C, the release of FGF1 and Myc-S100A13 was
inhibited by treatment with (i) 2-deoxyglucose, a reagent that
inhibits ATP biosynthesis (31), and (ii) amlexanox and latrun-
culin, reagents that induce the collapse of actin cytoskeleton
through different mechanisms (16, 32). In addition, the release of
Myc-S100A13 and FGF1 was insensitive to treatment with brefel-
din A, a reagent that disrupts ER-Golgi communication (30).
Since Myc-S100A13 is constitutively released from Myc-
S100A13 NIH 3T3 cell transfectants and its release is signifi-
cantly inhibited by the expression of FGF1, we evaluated the
pharmacological properties of the constitutive release of
S100A13. We observed that, like the constitutive release of p40
Syt1 (8), the constitutive release of Myc-S100A13 is insensitive
to amlexanox, 2-deoxyglucose, brefeldin A, actinomycin D, and
cycloheximide (data not shown). In contrast, amlexanox and
2-deoxyglucose are able to repress the release of both FGF1
and Myc-S100A13 in response to heat shock from FGF1 and
Myc-S100A13 NIH 3T3 cell cotransfectants. Furthermore,
while FGF1 is able to repress the release of S100A13, it is not
able to repress the constitutive release of p40 Syt1 (8). These
data suggest that the constitutive release of both Myc-S100A13
and p40 Syt1 occurs using pathways divergent from the stress-
dependent pathway of FGF1 release and also argues that the
constitutive release pathways exhibited by Myc-S100A13 and
p40 Syt1 (8) may be different.
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Myc-S100A13 May Be Released as a Complex with FGF1 in
Response to Heat Shock—The term S100 refers to the ability of
S100 gene translation products to be resistant to precipitation
at 100% (w/v) ammonium sulfate saturation (18). In contrast,
FGF1 is precipitated by ammonium sulfate fractionation at
85% (w/v) saturation (33), and ammonium sulfate fractionation
has been utilized to fractionate FGF1 from numerous organs
and tissues (9, 34). To evaluate the ability of S100A13 to be
precipitated by ammonium sulfate fractionation, we performed
100% (w/v) ammonium sulfate fractionation using media con-
ditioned by heat shock from Myc-S100A13 NIH 3T3 cell trans-
fectants. Following dialysis, pellets and supernatants from the
100% (w/v) ammonium sulfate fractionated media were ad-
sorbed to heparin-Sepharose and eluted with 1.5 M NaCl. As
anticipated, Myc immunoblot analysis revealed that Myc-
S100A13 released by the Myc-S100A13 NIH 3T3 cell transfec-
tants in response to heat shock was present only in the super-
natant fraction (data not shown).
Because these data suggested that Myc-S100A13 may be
resistant to precipitation following 100% (w/v) ammonium sul-
fate fractionation, we hypothesized that if Myc-S100A13 is
complexed with FGF1 as a result of stress-induced release, the
Myc-S100A13- and FGF1-containing complex should be char-
acterized by enhanced solubility of FGF1 in the supernatant
fraction following 100% (w/v) ammonium sulfate saturation. To
assess this premise, media conditioned by heat shock from
Myc-S100A13 and FGF1 NIH 3T3 cell cotransfectants and
from insert-less vector and FGF1 NIH 3T3 cell cotransfectants
were subjected to 100% (w/v) ammonium sulfate fractionation
and pellet and supernatant fractions obtained by centrifuga-
tion. After DTT treatment, pellet and supernatant fractions
were adsorbed to heparin-Sepharose, eluted at 1.5 M NaCl, and
the presence of FGF1 and Myc-S100A13 assessed by FGF1 and
Myc immunoblot analysis. As shown in Fig. 4A, higher levels of
FGF1 were resolved in the pellet fraction from media obtained
from temperature-stressed insert-less vector and FGF1 NIH
3T3 cell cotransfectants, whereas media obtained from temper-
ature-stressed Myc-S100A13 and FGF1 NIH 3T3 cell cotrans-
fectants exhibited increased levels of FGF1 and Myc-S100A13
in the supernatant fraction. These data suggest that Myc-
S100A13 may be able to alter the solubility of FGF1 in media
conditioned by heat shock, and the solubility of FGF1 under
conditions of 100% (w/v) ammonium sulfate saturation may
be a consequence of an association between FGF1 and
Myc-S100A13.
A S100A13 Mutant Lacking the Basic Residue-rich Domain
Functions as a Dominant Negative Regulator of FGF1 Re-
lease—The carboxyl-terminal domains of several S100 proteins
have been described as the structural regions responsible for
mediating the interaction between S100 polypeptides and spe-
cific target proteins (17, 18). Because the carboxyl terminus of
S100A13 (last 11 amino acid residues) is characterized by the
presence of 6 basic amino acid residues (Fig. 5A), a feature
absent in the other members the S100 protein family (19), we
evaluated whether the carboxyl-terminal basic residue-rich do-
main present in S100A13 is involved in the release of FGF1 and
Myc-S100A13. We produced a deletion mutant of Myc-S100A13
(Myc-S100A13D88–98) lacking the last 11 residues at the car-
boxyl terminus of the protein and cotransfected FGF1 NIH 3T3
cell transfectants with this deletion mutant. Analysis of the
heparin affinity of the Myc-S100A13D88–98 mutant obtained
from cell lysates of the FGF1 and Myc-S100A13D88–98 NIH
3T3 cell cotransfectants demonstrated that the Myc-
S100A13D88–98 protein is devoid of heparin affinity (data not
shown), suggesting that the basic residue-rich region of Myc-
S100A13 may be responsible for its ability to associate with
heparin.
We also evaluated the ability of the FGF1 and Myc-
S100A13D88–98 NIH 3T3 cell cotransfectants to release FGF1
and the Myc-S100A13D88–98 deletion mutant in response to
temperature stress. The FGF1 and Myc-S100A13 NIH 3T3 cell
cotransfectants were used as a positive control. The cotransfec-
FIG. 3. Pharmacology of FGF1 and Myc-S100A13 release in
response to temperature stress. A and B, the ability of Myc-
S100A13 to overcome the requirement for transcription and translation
for FGF1 release in response to temperature stress. Myc-S100A13 and
FGF1 NIH 3T3 cell cotransfectants (B) and insert-less vector and FGF1
NIH 3T3 cell cotransfectants (A) were incubated for 2 h at 37 °C in the
presence and absence of 10 mg/ml cycloheximide or 10 mg/ml actinomy-
cin D and then either subjected to heat shock (110 min at 42 °C) or
incubated for 110 min at 37 °C in the presence and absence of the same
concentration of the two reagents. Conditioned media were treated with
0.1% (w/v) DTT, adsorbed to heparin-Sepharose, and eluted at 1.5 M
NaCl. Eluted proteins were concentrated, resolved by 15% (w/v) SDS-
PAGE, and analyzed by FGF1 and Myc immunoblot analysis. A, FGF1
immunoblot analysis. B, upper panel, FGF1 immunoblot analysis; lower
panel, Myc immunoblot analysis. Lanes 1 and 2, media conditioned at
37 and 42 °C from control cells; lanes 3 and 4, media conditioned at 37
and 42 °C from cells incubated with cycloheximide; lanes 5 and 6, media
conditioned at 37 and 42 °C from cells incubated with actinomycin D. C,
effect of amlexanox, latrunculin, 2-deoxyglucose, and brefeldin A on
FGF1 and Myc-S100A13 release in response to temperature stress.
Myc-S100A13 and FGF1 NIH 3T3 cell cotransfectants were subjected to
heat shock in the presence and absence of 0.375 mM amlexanox, 400 nM
latrunculin, 50 mM 2-deoxyglucose, and 0.5 mg/ml brefeldin A. For the
evaluation of brefeldin A and 2-deoxyglucose activity, the cells were
pretreated prior to the heat shock with the same concentrations of the
reagents for 30 and 60 min, respectively, and conditioned media were
collected and processed as described above. Upper panel, FGF1 immu-
noblot analysis; lower panel, Myc immunoblot analysis: lanes 1 and 2,
media conditioned at 37 and 42 °C from control cells; lanes 3 and 4,
media conditioned at 37 and 42 °C from amlexanox-treated cells; lanes
5 and 6, media conditioned at 37 and 42 °C from latrunculin-treated
cells; lanes 7 and 8, media conditioned at 37 and 42 °C from 2-deoxy-
glucose-treated cells; lanes 9 and 10, media conditioned at 37 and 42 °C
from brefeldin A-treated cells. The figure is a composite of several
experiments.
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tants were subjected to heat shock and, following DTT treat-
ment, the conditioned media were either adsorbed to heparin-
Sepharose for the evaluation of FGF1 release or concentrated
and immunoprecipitated with an anti-Myc antibody for an
evaluation of Myc-S100A13D88–98 release. FGF1 immunoblot
analysis demonstrated that while FGF1 was present in media
conditioned by temperature stress from FGF1 and Myc-
S100A13 NIH 3T3 cell cotransfectants, FGF1 was not detected
in media conditioned by heat shock from FGF1 and Myc-
S100A13D88–98 NIH 3T3 cell cotransfectants (Fig. 5B). In
contrast, however, Myc-S100A13D88–98 was present in media
conditioned by heat shock from the FGF1 and Myc-S100A13D
88–98 NIH 3T3 cell cotransfectants (Fig. 5C). These data sug-
gest that the basic residue-rich domain in Myc-S100A13 may
not be required for the heat shock-induced export of Myc-
S100A13, but this domain may be necessary for the export of
FGF1 into the extracellular compartment in response to tem-
perature stress.
The Expression of Myc-S100A13 Induces the Release of Cys-
free FGF1 in Response to Temperature Stress—We have previ-
ously reported that (i) FGF1 is released as a homodimer in
response to heat shock (3, 6), (ii) a Cys-free mutant of FGF1 is
not able to access the extracellular compartment in response to
stress (6), and (iii) residue Cys30 in FGF1 is responsible for
dimer formation and export into the extracellular compartment
(35). Since the solubility of extracellular FGF1 under condi-
tions of 100% (w/v) ammonium sulfate saturation suggests that
S100A13 and FGF1 may be able to associate, we evaluated
whether S100A13 was able to affect the release of the Cys-free
mutant of FGF1. As a result, the Cys-free FGF1 NIH 3T3 cell
transfectants were cotransfected with either Myc-S100A13 or
insertless vector, and media conditioned by temperature stress
from both cotransfectants were evaluated for the presence of
FGF1 and Myc-S100A13. FGF1 and Myc immunoblot analysis
revealed that while the Cys-free FGF1 mutant was not re-
leased in response to heat shock from the insertless vector
control and FGF1 cotransfectants, the Cys-free FGF1 mutant
was released in response to temperature stress in cells express-
ing both Cys-free FGF1 and the Myc-S100A13 chimera (Fig.
4C). In addition, the Myc-S100A13 and Cys-free FGF1 NIH
3T3 cell cotransfectants were also able to release Myc-S100A13
in response to heat shock (Fig. 4C). Moreover, as previously
described for the Myc-S100A13 and FGF1 NIH 3T3 cell co-
transfectants, Cys-free FGF1 was also able to suppress the
constitutive release of Myc-S100A13 (Fig. 4C). The heat shock-
induced release of Cys-free FGF1 and Myc-S100A13 from Cys-
FIG. 4. Ammonium sulfate fractionation and the release of FGF1 and Myc-S100A13 in response to heat shock. A, solubility of
Myc-S100A13 and FGF1 at ammonium sulfate saturation. Myc-S100A13 and FGF1 NIH 3T3 cell cotransfectants and insertless vector and FGF1
NIH 3T3 cell cotransfectants were subjected to heat shock; conditioned media were collected and subjected to 100% (w/v) ammonium sulfate
fractionation; and pellet and supernatant fractions were obtained by centrifugation. After DTT treatment, the pellet and supernatant fractions
were adsorbed to heparin-Sepharose, eluted at 1.5 M NaCl, resolved by 15% (w/v) SDS-PAGE, and evaluated by FGF1 and Myc immunoblot
analysis. Upper panel, FGF1 immunoblot analysis; lower panel, Myc immunoblot analysis. Lanes 1 and 2, 37 and 42 °C supernatant fractions from
Myc-S100A13 and FGF1 NIH 3T3 cell cotransfectants; lanes 3 and 4, 37 and 42 °C pellet fractions from Myc-S100A13 and FGF1 NIH 3T3 cell
cotransfectants; lanes 5 and 6, 37 and 42 °C supernatant fractions from insert-less vector and FGF1 NIH 3T3 cell cotransfectants; lanes 7 and 8,
37 and 42 °C pellet fractions from insertless vector and FGF1 NIH 3T3 cell cotransfectants. B, solubility of Myc-S100A13 and Cys-free FGF1 at
ammonium sulfate saturation. Myc-S100A13 and Cys-free FGF1 NIH 3T3 cell cotransfectants were subjected to heat shock; conditioned media
were collected and subjected to 100% (w/v) ammonium sulfate fractionation; and pellet and supernatant fractions were obtained as described above
and analyzed by FGF1 and Myc immunoblot analysis. Upper panel, FGF1 immunoblot analysis; lower panel, Myc immunoblot analysis. Lanes 1
and 2, 37 and 42 °C pellet fractions from Myc-S100A13 and Cys-free FGF1 NIH 3T3 cell cotransfectants; lanes 3 and 4, 37 and 42 °C supernatant
fractions from Myc-S100A13 and Cys-free FGF1 NIH 3T3 cell cotransfectants. C, ability of Myc-S100A13 to export Cys-free FGF1 in response to
temperature stress. Myc-S100A13 and FGF1, Myc-S100A13 and Cys-free FGF1, and insertless vector and Cys-free FGF1 NIH 3T3 cell cotrans-
fectants were subjected to heat shock, and conditioned media were collected, treated with 0.1% (w/v) DTT, adsorbed to heparin-Sepharose, and
eluted with 1.5 M NaCl. The eluted fractions were resolved by 15% (w/v) SDS-PAGE and analyzed by FGF1 and Myc immunoblot analysis. Upper
panel, FGF1 immunoblot analysis; lower panel, Myc immunoblot analysis. Lane 1, total cell lysate from Myc-S100A13 and FGF1 NIH 3T3 cell
cotransfectants; lane 2, total cell lysate from insert-less vector and Cys-free FGF1 NIH 3T3 cell cotransfectants; lane 3, total cell lysate from
Myc-S100A13 and Cys-free FGF1 NIH 3T3 cell cotransfectants; lanes 4 and 5, media conditioned at 37 and 42 °C from Myc-S100A13 and FGF1
NIH 3T3 cell cotransfectants; lanes 6 and 7, media conditioned at 37 and 42 °C from Myc-S100A13 and Cys-free FGF1 NIH 3T3 cell cotransfectants;
lanes 8 and 9, media conditioned at 37 and 42 °C from insert-less vector and Cys-free FGF1 NIH 3T3 cell cotransfectants.
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free FGF1 and Myc-S100A13 NIH 3T3 cell cotransfectants (i)
occurred with kinetics similar to that observed for the release
of FGF1, (ii) was sensitive to amlexanox and 2-deoxyglucose
treatment, two reagents that are able to inhibit the stress-
induced release of FGF1 (6, 7), (iii) was insensitive to brefeldin
A, a feature also exhibited by the release of FGF1, and (iv) was
insensitive to treatment with actinomycin D and cycloheximide
(data not shown). These data suggest that the expression of
Myc-S100A13 may be able to affect the release of FGF1 either
as a monodimer or as a noncovalent dimer.
Since our results have suggested that Myc-S100A13 is able
to (i) associate with FGF1 in response to temperature stress
and (ii) induce the temperature-dependent release of Cys-free
FGF1, we evaluated the capacity of Myc-S100A13 to be re-
leased in association with Cys-free FGF1. Myc-S100A13 and
Cys-free FGF1 NIH 3T3 cell cotransfectants were subjected to
heat shock, conditioned media were collected and fractionated
at 100% (w/v) ammonium sulfate, and pellet and supernatant
fractions were obtained. As shown in Fig. 4B, FGF1 and Myc
immunoblot analysis revealed the presence of significant levels
of Cys-free FGF1 and Myc-S100A13 in the supernatant frac-
tion, suggesting that Myc-S100A13 may also be able to associ-
ate with the monomeric form of FGF1 under conditions of
temperature stress.
DISCUSSION
Our data suggest that S100A13 is involved in the regulation
of the stress-induced FGF1 release pathways. Thus, like the
stress-induced release of FGF1 (3), p40 Syt1 (7, 8), and murine
IL-1a (14), the stress-induced release of Myc-S100A13 is sen-
sitive to agents that interfere with ATP biosynthesis and orga-
nization of the F-actin cytoskeleton but is insensitive to disrup-
tion of intracellular communication between the ER-Golgi
apparatus. However, several observations suggest that
S100A13, unlike p40 Syt1, is able to facilitate the release of
FGF1. Indeed, expression of Myc-S100A13 was able to over-
come the inhibitory activity of actinomycin and cycloheximide
on FGF1 release and was able to induce the release of Cys-free
FGF1 in response to stress, suggesting a functional role for
S100A13 in the FGF1 release pathway as a potential modifier
of a stress-induced post-translational event.
The finding that Myc-S100A13 expression is able to over-
come the requirement for transcription and translation in the
release of FGF1 is consistent with the observation that some
members of the S100 gene family have been characterized not
only as stress-induced genes (36–39) but also as Cu21-binding
proteins (17, 18, 40, 41). It is interesting to note that S100B
was independently characterized from neural tissue as an in-
hibitor of Cu21-mediated L-ascorbate oxidation (40). Moreover,
S100A4, S100A6, S100A7, and S100B are up-regulated in sev-
eral human tumor cells, where they are associated with in-
creased invasiveness of transformed cells and acquisition of
metastatic phenotype (17). The murine analog of S100A8, the
CP-10 protein, has been also associated with inflammation,
since it is expressed and released in macrophages and endo-
thelial cells only after their activation by interleukin-1 and
lipopolysaccharide (17, 42). However, the observation that the
S100A13 gene is not induced in response to heat shock in NIH
3T3 cells does not eliminate the possibility that other members
of the S100 gene family may participate in the release of FGF1
and that the expression of S100A13 may compensate for their
function.
While it is difficult to anticipate how S100A13 participates in
these release pathways, we suggest that S100A13 may be able
to orient FGF1 and Cys-free FGF1 in a manner that enables
these polypeptides to form noncovalent homodimers. Indeed,
Cu21 oxidation is able to induce FGF1 homodimer (26) and
FGF1 IL-1a heterodimer formation (26). Additional evidence
from S100 crystallographic studies demonstrates that mem-
bers of the S100 gene family are able to form stable Ca21-
independent homodimers and through an alteration in their
conformation enable the two EF-hands in S100 to hold polypep-
tides, such as annexin 2 (Anx2) (43), enabling the carboxyl-
terminal domain of the polypeptide to interact with other pro-
teins (17, 18). In studies utilizing the interaction between
S100A11 and Anx1 (44, 45) as well as between S100A10 and
Anx2 (43), the orientation established by these conformational
changes yields the formation of stable heterotetramers
(S100A112zAnx12 and S100A102zAnx22). In the situations with
FGF1, it is intriguing to speculate that S100A13 may be able to
form similar heterotetramers with these polypeptides. Indeed,
this may explain how S100A13 is able to facilitate the release
of Cys-free FGF1, since it is possible that when interacting
with native FGF1, S100A13 may be able to orient its confor-
mation to expose Cys30, which is not exposed to solvent in its
native conformation (46), for FGF1 homodimer oxidation. In
the absence of Cys30, S100A13 may enable Cys-free FGF1 to
form the noncovalent equivalent of the FGF1 Cys30 homodimer
as a component of a FGF2zS100A132 heterotetramer so that it
can be released in response to heat shock. This would be con-
sistent with the observation that the stress-induced release of
Cys-free FGF1 and Myc-S100A13 exhibits similar kinetics and
responsiveness to pharmacological agents including amlex-
anox, 2-deoxyglucose, brefeldin A, cycloheximide, and actino-
FIG. 5. Ability of Myc-S100A13D88–98 to inhibit the release of
FGF1 in response to temperature stress. A, schematic illustration
of the domain structure of S100A13 (top) and the deletion mutant
S100A13D88–98 (bottom). B, Myc-S100A13 and FGF1 and
S100A13D88–98 and FGF1 NIH 3T3 cell cotransfectants were sub-
jected to heat shock, and, following DTT treatment, conditioned media
were either adsorbed to heparin-Sepharose for evaluation of FGF1
release or concentrated and immunoprecipitated with anti-Myc anti-
body for the evaluation of Myc-S100A13D88–98 and Myc-S100A13 re-
lease. Eluted and immunoprecipitated proteins were resolved by 15%
(w/v) and 12% (w/v) SDS-PAGE, respectively, and evaluated by FGF1
and Myc immunoblot analysis. Upper panel, FGF1 immunoblot analy-
sis; lower panel, Myc immunoblot analysis. Lane 1, cell lysate from
Myc-S100A13 and FGF1 NIH 3T3 cell cotransfectants; lane 2, cell
lysate from Myc-S100A13D88–98 and FGF1 NIH 3T3 cell cotransfec-
tants; lanes 3 and 4, media conditioned at 37 and 42 °C from Myc-
S100A13 and FGF1 NIH 3T3 cell cotransfectants; lanes 5 and 6, media
conditioned at 37 and 42 °C from Myc-S100A13D88–98 and FGF1 NIH
3T3 cell cotransfectants.
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mycin D (data not shown). In addition, the S100A13-dependent
increase in the solubility of Cys-free FGF1 under conditions of
100% (w/v) ammonium sulfate saturation also supports the
premise that S100A13 may be able to associate with the mo-
nomeric form of FGF1 in response to temperature stress, and
this association may involve the formation of a noncovalent
heterotetramer complex that may enable Cys-free FGF1 to
access the release pathway. Interestingly, the ability of
S100A13 to force FGF1 into the supernatant fraction under
conditions of saturated ammonium sulfate fractionation would
be consistent with this suggestion, since solubility in ammo-
nium sulfate is well described as being sensitive to alterations
in protein conformation (47).
It is interesting that latrunculin and amlexanox, which are
known to attenuate the F-actin cytoskeleton (16, 32), also in-
hibit the heat shock-induced release of FGF1 and Myc-
S100A13. Indeed, this suggests that the cytoskeleton may play
an important role in the FGF1 release pathway. The premise is
further supported by the association of the members of the
S100 gene family with actin stress fibers, which is dependent
upon the physiological status of the cell (48). As a result, it is
possible that S100A13 may act as an adaptor between FGF1
and F-actin structures. The F-actin cytoskeleton may be in-
volved in at least two stages of the stress-induced release of
FGF1 and Myc-S100A13: (i) the transport of the complex to the
cell membrane proceeding along F-actin stress fibers with the
potential participation of myosin molecular motors (49) and (ii)
exocytosis, which has been demonstrated to depend on the
submembrane actin cortex during classical protein secretion
(50). Because both actin-dependent transport and exocytosis
are energy-dependent processes (50), this suggestion is consist-
ent with the ability of 2-deoxyglucose to repress the stress-
induced release of FGF1 and Myc-S100A13. Interestingly, un-
like latrunculin (32), amlexanox does not interfere with the
stability of submembrane F-actin (16), and this further implies
that the F-actin stress fibers may be involved in the regulation
of the transport of FGF1, p40 Syt1, and Myc-S100A13 in the
nonclassical release of these polypeptides.
The observation that S100A13 is constitutively released in
vitro is also noteworthy, since a similar observation has been
made with the intracellular p40 fragment of p65 Syt1 (8).
Interestingly, the function of the C2A domain in p40 Syt1 has
been implicated in lipid bilayer penetration (51). However,
unlike p40 Syt1, which exhibits constitutive release in FGF1
NIH 3T3 cell transfectants (8), the expression of FGF1 in
Myc-S100A13 NIH 3T3 cell transfectants represses the consti-
tutive release of Myc-S100A13. Although it is difficult to inter-
pret the significance of these data, it is possible that the ability
of FGF1 to attenuate constitutive release of Myc-S100A13 but
not the constitutive release of p40 Syt1 may reflect the ability
of intracellular FGF1 to prefer an association with S100A13
rather than with p40 Syt1. Indeed, the observation that FGF1,
S100A13, and p40 Syt1 are present as a noncovalent aggregate/
complex in neural tissue suggests that the self-aggregration
properties attributed to both the extravesicular p40 domain of
p65 Syt1 (52) and S100 gene family members (17, 18) may be
involved in the arrangement of a conformation-sensitive aggre-
gate complex that may facilitate the release of FGF1. The
observations that FGF1 (35), p40 Syt1 (53), and S100A13 (54)
are able to associate with acidic phospholipids further suggest
an additional complexity to the stoichiometric interactions be-
tween these polypeptides.
Although we do not know how this multiprotein aggregate/
complex gains access to the extracellular compartment, it is
likely that the basic residue-rich domain at the carboxyl ter-
minus of S100A13 may be involved in regulating this function.
Several studies have reported that the carboxyl-terminal do-
main of S100 proteins is involved in mediating the interaction
of S100 polypeptides in their dimeric state with their target
proteins (17, 18). Because deletion of the basic residue-rich
domain at the carboxyl terminus of Myc-S100A13 results in the
generation of a dominant-negative effector of FGF1 release in
response to temperature stress, it is likely that this domain
may be involved in the regulation of FGF1 export under heat
shock conditions. However, it is unlikely that the S100A13
basic residue-rich domain is involved in mediating the ability of
Myc-S100A13 to traverse the plasma membrane, since the
Myc-S100A13D88–98 mutant is released in response to heat
shock. This is consistent with the observations that members of
the S100 gene family lacking a basic residue-rich domain at
their carboxyl terminus are released into the extracellular com-
partment following expression in mammalian cells (17, 18, 21)
and may imply that the carboxyl-terminal basic residue-rich
domain in S100A13 functions to associate with target proteins,
while the remainder of the S100A13 may be involved in pene-
tration through the lipid bilayer. Indeed, S100B and S100A10
do not contain a basic residue-rich domain, yet S100B is re-
leased by glial cells (55, 56), and S100A10 has been reported
not only to associate with plasminogen in the extracellular
compartment but is able to stimulate tissue-dependent plas-
minogen activation either alone or as a complex with Anx2 (57).
These and other studies (58, 59) have implicated the function of
S100, Anx2, and phosphatidylserine as key mediators of the
extrinsic coagulation and fibrinolytic systems on the surface of
the endothelial cell (57–59). Further, phosphatidylserine flip-
ping from the inner leaflet to the outer leaflet of the plasma
membrane is known to be a regulator of vascular hemostasis
(60), and phosphatidylserine is also able to flip to the outer
leaflet of the plasma membrane in response to heat shock (60).
Because all of the known components of the stress-induced
FGF1 release pathway have been characterized as phosphati-
dylserine-binding proteins (35, 53, 54) and S100A13 has been
characterized as an Anx2-binding protein (61), we anticipate
that Anx2 and phosphatidylserine flipping may be involved in
mediating the export of these polypeptides.
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